SecBot SecBot

ADXN

Addex Therapeutics Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. V8· CIK 0001574232 Biotech & Drug Discovery
$2.97 +0.08 (+2.70%)
Oct 23 4:00 PM ET · prev $2.89
Market cap
$4.9M
Nano cap
1 year
−69.1%
from $9.60 · Oct 24
30 days
−14.2%
from $3.46
52-week range
$2.65–9.92
−70% from high · low Oct 14
Avg volume 20D
12.8K
Sep 28 spike 90.7K
Short interest
1.8K
≈0.1% of shares · +589.1%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q4 2025 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 2 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 4/5
Strongest BEARISH Addex Therapeutics reported H1 2026 financial results showing a net loss of CHF 3.5 million (vs CHF 3.3…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q4 2025: 1 added (0 new), 0 trimmed or exited.

  • Short sellersBUILDING

    Short interest +589.1% to 1.8K shares. 1.0 days to cover, ≈0.1% of shares.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F· Q4 2025
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED156$1.2K
MORGAN STANLEYNEAR_EXIT100$734.00
RHUMBLINE ADVISERSTRIM72$528.00
MORGAN STANLEYDOUBLED1,900$13.3K
RHUMBLINE ADVISERSDOUBLED107$749.00
MORGAN STANLEYNEAR_EXIT353$3.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2024
Recent actions
DateFirmActionRating
Jul 31, 2024HC Wainwright & Co.
UPGRADE
UPGRADEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 28, 2026
Trading halt
Halt Resumed: ADXN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-28T15:24:40.000Z | Resumed 2026-09-28T15:29:40.000Z
Sep 28, 2026
Trading halt
Trading Halt: ADXN — LUDP (Volatility Trading Pause)
Addex Therapeutics Ltd ADS | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 20, 2026
Trading halt
Halt Resumed: ADXN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-20T19:41:44.000Z | Resumed 2026-08-20T19:46:44.000Z
Aug 20, 2026
Trading halt
Trading Halt: ADXN — LUDP (Volatility Trading Pause)
Addex Therapeutics Ltd ADS | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 20, 2026
Trading halt
Halt Resumed: ADXN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-20T19:30:41.000Z | Resumed 2026-08-20T19:35:41.000Z

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 2, 2026
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER
AWARD65,620 sh
Sep 2, 2026
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER
TO ISSUER30,000 sh
Sep 2, 2026
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER
AWARD59,530 sh
Sep 2, 2026
Kalinichev Mikhail
HEAD OF TRANSLATIONAL SCIENCE
TO ISSUER200,000 sh
Sep 2, 2026
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER
TO ISSUER90,529 sh
Sep 2, 2026
Kalinichev Mikhail
HEAD OF TRANSLATIONAL SCIENCE
AWARD306,765 sh
Sep 2, 2026
Manke Isaac
Director
AWARD219,561 sh
Sep 2, 2026
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER
TO ISSUER65,620 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
1,840
shares short
+589.1%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Trading halts
Sep 28, 2026Volatility PauseResumed
Aug 20, 2026Volatility PauseResumed
Aug 20, 2026Volatility PauseResumed
Aug 20, 2026Volatility PauseResumed
Aug 20, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 8, 2026 SEC
Addex Therapeutics announced via 6-K that its spin-out Neurosterix completed Phase 1 studies of NTX-253 (M4 PAM for…
6-K — Impact 5/10
Oct 2, 2026 SEC
Addex Therapeutics announced executive management changes: Jean-Philippe Rocher appointed Head of Pharmaceutical…
6-K — Impact 3/10
Sep 28, 2026 Trading halt
Halt Resumed: ADXN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-28T15:24:40.000Z | Resumed 2026-09-28T15:29:40.000Z
Sep 28, 2026 SEC
Addex Therapeutics reported H1 2026 financial results showing a net loss of CHF 3.5 million (vs CHF 3.3 million in H1…
6-K — Impact 7/10
Sep 2, 2026 Insider
Teyssedou Lenaic Nathanael was granted 65,620 shares
PRINCIPAL ACCOUNTING OFFICER
Sep 2, 2026 Insider
Teyssedou Lenaic Nathanael disposed of 30,000 shares
PRINCIPAL ACCOUNTING OFFICER
Sep 2, 2026 Insider
Teyssedou Lenaic Nathanael was granted 59,530 shares
PRINCIPAL ACCOUNTING OFFICER
Dec 31, 2025 Inst.
UBS Group AG — DOUBLED
156 shares ($1.2K)

SecBot reports

11 filings · 2 bullish · 5 bearish · 4 neutral
All ADXN filing & press-release reports (11)